SHEN Li,FANG Wei,ZHANG Yao,et al.Retrospective analysis of coagulopathy in patients with severe renal insufficiency caused by tigecycline[J].ZHONGGUO YAOFANG,2023,34(22):2766-2769.
SHEN Li,FANG Wei,ZHANG Yao,et al.Retrospective analysis of coagulopathy in patients with severe renal insufficiency caused by tigecycline[J].ZHONGGUO YAOFANG,2023,34(22):2766-2769. DOI: 10.6039/j.issn.1001-0408.2023.22.14.
Retrospective analysis of coagulopathy in patients with severe renal insufficiency caused by tigecycline
To analyze the effects of tigecycline on coagulation function in patients with severe renal insufficiency, and to provide a reference for safe clinical drug use.
METHODS
2
Retrospective analysis was performed for the clinical data of patients with severe renal dysfunction complicated with infection receiving tigecycline admitted to nephrology department of our hospital from January 2021 to October 2022. The levels of prothrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR), platelet (PLT) and fibrinogen (FIB) were compared 3 days before medication, with 1-5, 6-10, 11-15 and 16-20 days after medication, 5 days after withdrawal and/or after symptomatic treatment.
RESULTS
2
Finally, 14 patients were included, and 9 patients developed coagulopathy, with an incidence of 64.29%. Compared with 3 days after medication, the levels of FIB at 6-10 and 11-15 days after medication, and PLT at 1-5 , 6-10 and 11-15 days after medication were decreased significantly, while the levels of PT at 1-5 and 6-10 days after medication, APTT at 1-5, 6-10 and 11-15 days after medication were significantly prolonged, and INR increased significantly at 1-5 and 6-10 days after medication (
P
<0.05). Compared with 3 days before medication, there were no statistically significant changes in FIB, PT, INR, APTT and PLT at 16-20 days after medication and 5 days after withdrawal and/or symptomatic treatment(
P
>0.05).
CONCLUSIONS
2
Patients with severe renal insufficiency should be cautious with tigecycline, which can lead to prolonged PT and APTT, increased INR, and decreased PLT and FIB. If medication time is over 14 days, dynamic monitoring of coagulation function indicators is recommended to reduce the risk of adverse reactions.
DONG W,XIE X Q,KANG Y. The interpretation of guideline of appropriate use of tigecycline[J]. Chin J Evid Based Med,2016,16(1):30-32.
KADOYAMA K,SAKAEDA T,TAMON A,et al. Adverse event profile of tigecycline:data mining of the public version of the U.S. Food and Drug Administration adverse event reporting system[J]. Biol Pharm Bull,2012,35(6):967-970.
Infection Group of Respiratory Society of Chinese Medical Association. Guidelines for the diagnosis and treatment of adult hospital-acquired pneumonia and ventilator-associated pneumonia in China:2018 edition[J]. Chin J Tuberc Respir Dis,2018,41(4):255-280.
Infectious Diseases Professional Committee of China Medical Education Association. Expert consensus on the clinical application of the pharmacokinetic/pharmacodynamics theory of antimicrobial drugs [J]. Chin J Tuberc Respir Dis,2018,41(6):409-446.
葛卫红,徐航.临床药师工作手册:抗栓治疗[M].北京:人民卫生出版社,2020:51-57.
GE W H,XU H.Clinical Handbook for clinical pharmacist:antithrombotic therapy[M]. Beijing:People’s Medical Publishing House,2020:51-57.
WANG M G. Laboratory diagnosis,clinical management and infection control of the infections caused by extensively drug-resistant Gram-negative bacilli:a Chinese consensus statement[J]. Chin J Infect Chemother,2017,17(1):82-92.
ZHANG J,ZHANG R. Effect of tigecycline on coagulation markers:a retrospective study[J]. J Third Mil Med Univ,2019,41(15):1485-1490.
PIERINGER H,SCHMEKAL B,BIESENBACH G,et al. Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline[J]. Ann Hematol,2010,89(10):1063-1064.
LIU J,YAN Y Y,ZHANG F. Risk factors for tigecycline-associated hypofibrinogenemia[J]. Ther Clin Risk Manag,2021,17:325-332.
YANG Y H,LI J,SONG H Z,et al. Analysis of relative factors of blood coagulation abnormality caused by tigecycline[J]. Chin J N Drugs Clin Remedies,2022,41(1):52-56.
SHI S P,WU X,NONG J C,et al. Influencing factors of coagulation abnormalities induced by cefoperazone/sulbactam[J]. Chin J Pharmacoepidemiol,2019,28(9):578-580,590.
HU J,XIAO Y H,ZHENG Y,et al. Clinical characteristics and risk factors of tigecycline-associated hypofibrinogenaemia in critically ill patients[J]. Eur J Clin Pharmacol,2020,76(7):913-922.
LYU P,WANG Y H,FAN H H,et al. Risk factors and potential mechanisms of hypofibrinogenemia induced by tigecycline[J]. Chin J Hosp Pharm,2021,41(15):1587-1590.